Clinical Trial Update: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). [Phase 1, Phase 2]

View source ↗

Summary

This Clinical Trial Update describes a fourth-generation CD19/CD22 dual-targeting CAR T-cell therapy being evaluated in Phase 1/2 for highly resistant B-cell ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma
• Central Nervous System Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• CD19/CD22 dual-targeting fourth-generation CAR T cells (CAR T cells targeting CD19 and CD22)

Snippet

Sponsor: Essen Biotech | Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse | Phase 1, Phase 2 | Status: RECRUITING